ImmuCell (ImmuCell) Debt-to-Asset : 0.38 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is ImmuCell Debt-to-Asset?

ImmuCell's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.07 Mil. ImmuCell's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $14.62 Mil. ImmuCell's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $43.81 Mil. ImmuCell's debt to asset for the quarter that ended in Dec. 2023 was 0.38.

ImmuCell Debt-to-Asset Historical Data

The historical data trend for ImmuCell's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuCell Debt-to-Asset Chart

ImmuCell Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.22

0.27

0.23

0.28

0.38

ImmuCell Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.28	0.31	0.34	0.38	0.38

Competitive Comparison of ImmuCell's Debt-to-Asset

For the Biotechnology subindustry, ImmuCell's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmuCell's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmuCell's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ImmuCell's Debt-to-Asset falls into.

ImmuCell Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ImmuCell's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.073	+	14.618)	/	43.808
	=	0.38

ImmuCell's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.073	+	14.618)	/	43.808
	=	0.38

ImmuCell (NAS:ICCC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

ImmuCell Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of ImmuCell's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuCell (ImmuCell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuCell Corp (NAS:ICCC) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

IUL:Germany

Address

56 Evergreen Drive, Portland, ME, USA, 04103

Website

https://www.immucell.com

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. It has two segments Scours and Mastitis. The company generates the majority of its revenue from the United States.

Executives

Bryan K. Gathagan	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
David Cunningham	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Gloria F Basse	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
David Scott Tomsche	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Steven T. Rosgen	director	C/O IMMUCELL CORPORATION, 56 EVERGREEN DR., PORTLAND ME 04103
Norman H Pessin	other: See Explanation of Responses	C/O LEVY, HARKINS & CO., INC., 366 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Brian L. Pessin	other: See Explanation of Responses	310 EAST 75TH STREET, APT. 2A, NEW YORK NY 10021
Joseph H Crabb	director, officer: Vice President and CSO	IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Elizabeth Luttrell Williams	officer: Vice Pres. of Mfg Operations	C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Jonathan E Rothschild	director, 10 percent owner	C/O IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Linda Rhodes	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Paul R Wainman	director	56 EVERGREEN DRIVE, PORTLAND ME 04103
Michael F Brigham	director, officer: President and CEO	IMMUCELL CORP, 56 EVERGREEN DRIVE, PORTLAND ME 04103
Bobbi Jo Kunde	other: Director of Sales and Marketin	56 EVERGREEN DRIVE, PORTLAND ME 04103
Robert C Bruce	director	56 EVERGREEN DRIVE, PORTLAND ME 04103